News, infos and good to know WKN: A2QQ2E ISIN: US45256X1037 Forum: Aktien User: Lirumlarum1

https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-expands-access-anktivar-eu-new-distribution?field_nir_news_date_value[min]=

https://www.businesswire.com/news/home/20260218759994/en/ImmunityBio-Receives-Authorization-from-the-European-Commission-for-ANKTIVA-with-BCG-for-Non-Muscle-Invasive-Bladder-Cancer-Carcinoma-in-Situ-Expanding-Global-Access-to-33-Countries

https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-reports-productive-regulatory-engagement-saudi-food?field_nir_news_date_value[min]=

https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-launches-phase-2-chemotherapy-free-car-nk-cell?field_nir_news_date_value[min]=

https://youtu.be/kdKE1HcNMS0

https://de.investing.com/news/analyst-ratings/btig-hebt-kursziel-fur-immunitybio-nach-verbesserten-aussichten-auf-9-usdollar-ann-93CH-3311302

https://www.investing.com/news/analyst-ratings/hc-wainwright-raises-immunitybio-stock-price-target-to-10-on-anktiva-progress-93CH-4464972

ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-reports-median-overall-survival-not-yet-reached-and?field_nir_news_date_value[min]=

ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-advances-regulatory-discussions-fda-potential?field_nir_news_date_value[min]=

ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-advances-first-line-bcg-naive-nmibc-program?field_nir_news_date_value[min]=